In last trading session, the stock price of Cannabis Science Inc (OTCMKTS:CBIS) declined more than 3% to close the trading session at $0.0380. The decline came at a share volume of 5.18 million compared to monthly average share volume of 11.77 million. With this, the company’s market cap now stands at $48.72 million.
The highlights
Cannabis Science alleviates suffering and pain and promotes health using cannabinoid science. It is a leading biotech firm that creates CBD based extracts formulations for treatment of several medical conditions including over eight different types of cancer. Each of these formulations has earnings and revenue potential in the current global pharmaceutical market.
The potential earnings and revenue are combined with more profit centers including nutraceutical products, an educational model and a strategic association with MedBox® Solutions. These profit centers results in a higher confidence level to grasp overall financial plan and strategy to bring Cannabis Science into promising earnings per share by 2015. The CBD industry and market is best explained by the alcohol ban black market model of 1920’s, and then as a Pharma retail industry in the 1930’s.
The management view
The CBD market is projected at $30 billion to $50 billion, and the internal projections increases that number to over $70 billion upon speculation of approval of the Fed Medical Cannabis Program in year 2017. The management of Cannabis Science stated that they are focused on the relationship of quantum physics with biology, and the role the CBD strain plays in life. The Scientific Advisory Board of company is comprised of expert doctors who share the same vision.
In last trading session, the stock price of Cannabis Science Inc (OTCMKTS:CBIS) declined more than 3% to close the trading session at $0.0380. The decline came at a share volume of 5.18 million compared to monthly average share volume of 11.77 million.
